Daewon Pharmaceutical reported on the 14th that its consolidated financial statement sales in the first half of this year increased by 1.9% compared to the same period last year, reaching 301.7 billion won, while operating profit fell by 42.4% during the same period to 8 billion won.
The operating profit margin decreased by 2 percentage points to 2.7% compared to the same period last year.
The company explained that increased cost of sales and research and development expenses impacted the current performance.
A company official noted, "The cost of sales rose during the process of expanding the portfolio due to the introduction of new products," adding, "The overall factor for the decrease in operating profit lies in investments for growth, such as research and development and infrastructure expansion, and as such, we expect this to lead to improved revenue structure and strengthened market competitiveness in the medium to long term."